Annexon Biosciences: Tailwind from Analysts – Pipeline Progress and Price Potential in Focus
Reading Time: 3 minutes
In July, the analysis firms Wells Fargo and Needham reaffirmed their buy recommendations for Annexon Biosciences (ANNX) (i.) and indicated a significant price potential of up to 315%. Recent appearances in June and July 2026 at neurological and ophthalmological conferences underscore the progress of the lead compounds Tanruprubart and Vonaprument. The market is now focused on upcoming Phase 3 data and regulatory filings that could transition the company into the commercial phase. Innovative approach against neuroinflammatory diseases Annexon...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
